“Clinical studies”—
Are you referring to the single phase 2 trial that we are awaiting topline results that will determine whether the antiviral program is dead on arrival or alive and well?
There is only 1 clinical study.
And If they don’t meet primary end point don’t bother presenting an argument that they still have a Covid antiviral drug…you can’t with a straight face say if fail the trial they still have a hot desirable antiviral drug.
Amazing topline results for the single clinical
Study will
Determine, but as I have said, it’s not just the results but what happens in the first 30-45 days after the results, or risk more of the same from ipix with phase 2s
1) need amazing results
2) need monetize those results within 30
Days like the staff of 3 at ridgeback did with Merck…